← Back to Clinical Trials
Recruiting NCT04652609

NCT04652609 Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04652609
Status Recruiting
Phase
Sponsor Universidad de Granada
Condition Breast Neoplasm
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2021-01-01
Primary Completion 2025-01-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
PRESIONA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 25 participants in total. It began in 2021-01-01 with a primary completion date of 2025-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.

Eligibility Criteria

Inclusion Criteria: * 18 years or older * HER2+ breast cancer diagnosis * On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy) Exclusion Criteria: * Previous diagnosis of cancer * Pregnant * Cardiac pathology * No symptoms or pathology that could be confused with neuropathy or related to diabetes * No recommendation from oncologist for therapeutic exercise practice

Contact & Investigator

Central Contact

Irene Cantarero-Villanueva, PhD

✉ irenecantarero@ugr.es

📞 958248764

Principal Investigator

Irene Cantarero-Villanueva, PhD

PRINCIPAL INVESTIGATOR

Physical Therapy Deparment, Faculty of Health Sciences, University of Granada

Frequently Asked Questions

Who can join the NCT04652609 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Breast Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04652609 currently recruiting?

Yes, NCT04652609 is actively recruiting participants. Contact the research team at irenecantarero@ugr.es for enrollment information.

Where is the NCT04652609 trial being conducted?

This trial is being conducted at Granada, Spain.

Who is sponsoring the NCT04652609 clinical trial?

NCT04652609 is sponsored by Universidad de Granada. The principal investigator is Irene Cantarero-Villanueva, PhD at Physical Therapy Deparment, Faculty of Health Sciences, University of Granada. The trial plans to enroll 25 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology